Press Release
NeurogesX Appoints Thorsten von Stein MD. PhD. as Chief Medical Officer
Former Roche Pharmaceutical Executive to Lead Pain Treatment Product DevelopmentSan Carlos, Calif. - September 3, 2003
NeurogesX today announced it has appointed Thorsten von Stein, MD. PhD. as Chief Medical Officer. Dr. von Stein, who joined NeurogesX in 2001 as Vice President of Clinical Development, will assume responsibility for all medical aspects of the company’s strategy and operations.
"Since Thorsten has joined NeurogesX, he has been instrumental in effectively designing and guiding our lead clinical program forward toward regulatory approval and marketing," said Anthony A. DiTonno, CEO and President of NeurogesX. "His appointment as Chief Medical Officer recognizes his achievements and the progress of NeurogesX as we move ahead in the regulatory process on several fronts."
NeurogesX now has pivotal trials under way in the treatment of postherpetic neuralgia and painful HIV-associated neuropathy.
Dr. von Stein’s experience in the pharmaceutical industry includes several drug development positions in a variety of therapeutic areas. Before joining NeurogesX in 2001, he was Director of Medical Research at Roche Pharmaceuticals, where he led the advanced clinical development of ibandronate for osteoporosis, one of Roche’s top priority development projects. Prior to that, Mr. von Stein held management positions at Roche in clinical research, biometrics and project management. Before his work in the pharmaceutical industry, he managed software development projects and conducted research work in artificial intelligence applications for medicine.
Dr. von Stein received his MD from the University of Munich, Germany and a PhD in computer science from the University of Hamburg, Germany.
About NeurogesX
NeurogesX (neur-o-GEE-six) is a privately held specialty pharmaceutical company focusing on the development of products for the treatment of nerve signaling disorders. The company’s initial products are focused on the treatment of chronic and acute pain. The company’s first product, a topical treatment for neuropathic pain, has been evaluated in a Phase II randomized double-blind trial. Two phase II/ III multi-center clinical trials are currently enrolling patients. The company is also conducting Phase II/III trials for the treatment of painful HIV-associated neuropathy. NeurogesX has raised $30 million in total equity investments since its first funding round in June 2000. Investors include Alta Partners, ARCH Venture Partners, Montreux Equity Partners, Grove Street Advisors Affiliated Fund, TIAA (Teachers Insurance and Annuity Association), Duke University, University of North Carolina and Walden International.
For more information about NeurogesX, go to www.neurogesx.com.
NeurogesX is a trademark of NeurogesX, Inc. All other trademarks and registered trademarks are those of their respective companies.
Contacts:
Anthony A. DiTonno
CEO and President
NeurogesX, Inc.
aditonno@neurogesx.com
650-508-2116
Stephen F. Ghiglieri
CFO
NeurogesX, Inc.
sghiglieri@neurogesx.com
650-508-2116
Mike Jackman
Jackman Communications
mike@jackman.com
415-388-3216